Salvage surgery after chemo- or chemoradiotherapy for initially unresectable lung carcinoma
ConclusionsAlthough cardiopulmonary complications can accompany salvage surgery, the procedure is generally safe. Survival outcome is encouraging, especially in cases with good response to initial treatment.
ConclusionAtezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility.
Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and unique subtype of primary non-small cell lung cancer (NSCLC) that histologically resembles undifferentiated nasopharyngeal carcinoma (NPC) . It is recognized to be etiologically associated with Epstein-Barr virus (EBV) infection in endemic area . Currently, pulmonary LELC is classified as “other and unclassified carcinomas” according to the 2015 World Health Organization Classification Lung Tumors . Over the past decades, less than 600 cases have been reported in the literature.
In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy and first-line chemotherapy. In August 2015, appearance of leptomeningeal carcinomatosis triggered severe clinical deterioration and threatened the patient's life. Anti-PD1 immune checkpoint inhibitor Nivolumab was initiated in an attempt to stop tumour growth, achieving a spectacular brain and pulmonary complete response and clinical improvement, without serious adverse effects...
Lung cancer is the most common cause of cancer death worldwide1. Non-small cell lung carcinoma (NSCLC) accounts for around 85% of lung cancer cases. The standard treatment for patients with stage I and II NSCLC is surgery based, with or without postoperative chemotherapy depending on the pathological T and N status. Treatment for stage III NSCLC consists either of concurrent chemoradiation, or surgery with perioperative chemotherapy with or without thoracic radiotherapy2. After surgery, the 5-year survival rates range between 23 and 83%, depending on stage3.
ConclusionsThis first report of SBRT for pulmonary LCNEC demonstrates that SBRT is a feasible modality for this rare disease. A multidisciplinary thoracic oncology approach involving medical oncology, thoracic surgery, radiation oncology and pulmonology is strongly recommended to ensure proper patient selection for receipt of SBRT.
Conclusions: Pem + CT seemed to be more effective first-line regimen for advanced NSCLC with wild-type EGFR or ALK, especially for patients with NSCC. However, limitations of the study including methodological quality and immature OS data need to be considered. PMID: 31463119 [PubMed]
CONCLUSIONS: Although cardiopulmonary complications can accompany salvage surgery, the procedure is generally safe. Survival outcome is encouraging, especially in cases with good response to initial treatment. PMID: 31445048 [PubMed - as supplied by publisher]
Conditions: Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJC C v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 I...
We describe two patients with advanced non ‐small‐cell lung cancer (NSCLC), including one in whom the definitive diagnosis of pulmonary pleomorphic carcinoma (PPC) was made by histopathology of the resected tumour and another in whom the diagnosis of “favor adenocarcinoma containing sarcomatoid components” was made by tissue biopsy. Both were resistant to first line platinum‐based chemotherapy, but responded dramatically to second line nivolumab therapy. We present two cases of pulmonary pleomorphic carcinoma (PPC) treated with Nivolumab. A 57 ‐year‐old man presented with a 3.5‐cm mass in the left l...